Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > News release!

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Feb 23, 2021 4:10pm

91 Views

Post# 32639417

RE:RE:RE:RE:News release!

Besides its high cost, Adstiladrin doesn't appear to be usable in other cancer applications such as glioblastoma and lung.
This whole story is a lot of "meh" to me, but pat yourself on the back if you managed to shake some stop losses and get cheap shares.
And when efficacy rates are no longer impaired by poor application, TLD-1433 will be the clear front runner in this space!
GLTA! And have a great week!

coalbet wrote:

BOSTON, January 15, 2021 – The Institute for Clinical and Economic Review (ICER) today issued a revised Final Evidence Report that corrects a data entry error within the cost-effectiveness analysis of nadofaragene firadenovec (Adstiladrin®, FKD Therapies Oy and FerGene) for the treatment of non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guerin (BCG) intravesical therapy.

ICER’s health-benefit price benchmark (HBPB) range for nadofaragene firadenovec has been revised accordingly and is now $158,600-$262,000. The original version of this report, published on December 17, 2020, inaccurately stated that this range was $121,000-$201,000.